

ASX ANNOUNCEMENT
Wednesday 9th April 2025

New \$3.2M Contract Win Supports IDT Recommissioning of Australia's Largest Small Molecule API Plant

Highlights:

- **IDT Secures a manufacturing contract with Nacuity Pharmaceuticals Pty Ltd for NPI-001, an investigational treatment for retinitis pigmentosa (RP)**
- **Agreement terms are for five years with an initial \$3.2M statement of work that is expected to be completed by the end of FY2026**
- **Nacuity Pharmaceuticals received FDA Fast Track designation for RP, a progressive degenerative eye disease with no standard treatment that leads to vision loss**
- **IDT will recommission its 4,000L Active Pharmaceutical Ingredient (API) plant, making it the largest small molecule plant of its kind in Australia**
- **The recommissioned plant also gives IDT a strategic advantage for addressing potential drug shortages**

IDT Australia Limited (ASX: IDT) (**IDT** or the **Company**) is pleased to announce that it has been awarded a five-year contract for the current Good Manufacturing Practice (cGMP) manufacture of NPI-001 (N-acetylcysteine amide) tablets – a new and innovative investigational therapy for the treatment of patients with retinitis pigmentosa (**RP**).

The agreement, awarded by Nacuity Pharmaceuticals Pty Ltd, includes an initial statement of work for \$3.2M, which is expected to conclude at the end of FY2026, and allows for annual follow up contracts. A 10-fold scale-up in the production of the active ingredient of NPI-001 to circa 200kg, and the production of the finished dosage form (FDF) of the drug into circa 1 million tablets, positioning IDT for future clinical trials and commercial launch of the therapy.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Halden Conner, Chief Executive Officer of Nacuity Pharmaceuticals commented:

“Nacuity has continued to invest in Australian companies for their exceptional R&D and clinical trial capabilities. We selected IDT Australia for its world-class manufacturing facilities and unique ability to support our development program from clinical trials to commercial scale-up.”

The project will be executed at IDT's 4,000L cGMP manufacturing plant, which has been recommissioned for this initiative. This plant will be the largest small molecule Active Pharmaceutical Ingredient (API) facility in Australia and will present a strategic advantage for addressing potential drug shortage opportunities and other large scale API manufacturing needs.

Paul McDonald, the Chief Executive Officer of IDT Australia, said:

“We are excited to partner with Nacuity Pharmaceuticals Pty Ltd on the manufacture of this promising therapy for patients with RP, especially when there is no standard treatment for the disease. Our ability to support innovative clients from clinical trials to commercialisation is one reason why we have such a high rate of return work.”

The NPI-001 program has achieved Fast Track designation from the U.S. Food and Drug Administration (FDA), recognising its potential to address an unmet medical need for a serious disease and expedite its development and regulatory review. RP is a progressive degenerative eye disease that leads to vision loss.

Manufacturing activities for the NPI-001 project are already underway and are scheduled for completion by the end of the calendar year. This contract represents a significant milestone in IDT's strategy to expand its pharmaceutical manufacturing capabilities and leverage its expertise in the production of groundbreaking therapies.

Ends..../

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.